Latest Ratios: P/E Ratio 2.0x · EV/EBITDA 3.7x · ROE N/A. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $196M | $831M | $822M | $869M | $1.6B | — | — | — |
| Enterprise Value | $1.4B | $2.0B | $2.2B | $2.2B | $3.0B | — | — | — |
| P/E Ratio → | 2.04 | 8.71 | 10.52 | 12.34 | 7.40 | — | — | — |
| P/S Ratio | 0.18 | 0.77 | 0.73 | 0.78 | 1.45 | — | — | — |
| P/B Ratio | — | — | — | — | — | — | — | — |
| P/FCF | 1.08 | 4.56 | 41.33 | 21.10 | 4.23 | — | — | — |
| P/OCF | 1.02 | 4.34 | 23.04 | 12.84 | 3.99 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.88 | 1.93 | 1.95 | 2.62 | — | — | — |
| EV / EBITDA | 3.68 | 5.35 | 9.98 | 8.32 | 7.21 | — | — | — |
| EV / EBIT | 4.25 | 8.36 | 13.82 | 10.26 | 9.76 | — | — | — |
| EV / FCF | — | 11.16 | 108.71 | 52.94 | 7.61 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.9% | 62.9% | 64.9% | 66.9% | 68.6% | 68.7% | 70.3% | 70.9% |
| Operating Margin | 30.5% | 30.5% | 15.5% | 20.5% | 33.5% | 42.2% | 44.9% | 45.3% |
| Net Profit Margin | 8.8% | 8.8% | 7.0% | 6.3% | 19.8% | 35.6% | 39.4% | 39.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | 71.1% | 74.4% | 74.9% |
| ROA | 8.0% | 8.0% | 6.3% | 6.1% | 23.9% | 54.4% | 57.7% | 58.0% |
| ROIC | 42.7% | 42.7% | 23.9% | 37.8% | 55.8% | 63.0% | 63.3% | 65.3% |
| ROCE | 37.8% | 37.8% | 19.7% | 27.9% | 53.7% | 80.3% | 79.8% | 81.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.01 | — |
| Debt / EBITDA | 3.76 | 3.76 | 7.42 | 6.25 | 4.01 | — | 0.01 | — |
| Net Debt / Equity | — | — | — | — | — | 0.00 | 0.01 | 0.00 |
| Net Debt / EBITDA | 3.17 | 3.17 | 6.19 | 5.00 | 3.20 | 0.00 | 0.01 | 0.00 |
| Debt / FCF | — | 6.61 | 67.38 | 31.84 | 3.38 | 0.00 | 0.01 | 0.00 |
| Interest Coverage | 2.27 | 2.27 | 1.39 | 1.99 | 6.55 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.41 | 2.41 | 2.03 | 2.12 | 2.21 | 1.78 | 1.72 | 1.97 |
| Quick Ratio | 1.73 | 1.73 | 1.58 | 1.69 | 1.80 | 1.06 | 0.97 | 1.17 |
| Cash Ratio | 0.86 | 0.86 | 0.72 | 0.92 | 1.10 | — | — | — |
| Asset Turnover | — | 0.99 | 0.87 | 0.92 | 1.04 | 1.48 | 1.47 | 1.49 |
| Inventory Turnover | 2.24 | 2.24 | 2.30 | 2.44 | 2.89 | 3.09 | 3.17 | 3.20 |
| Days Sales Outstanding | — | 50.30 | 80.60 | 5.83 | 7.56 | 47.18 | 40.35 | 41.80 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 17.9% | 4.2% | 4.2% | 4.0% | 0.5% | — | — | — |
| Payout Ratio | 36.7% | 36.7% | 44.1% | 48.9% | 3.8% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 48.9% | 11.5% | 9.5% | 8.1% | 13.5% | — | — | — |
| FCF Yield | 92.9% | 21.9% | 2.4% | 4.7% | 23.6% | — | — | — |
| Buyback Yield | 2.9% | 0.7% | 0.4% | 0.4% | 0.0% | — | — | — |
| Total Shareholder Yield | 20.9% | 4.9% | 4.6% | 4.4% | 0.5% | — | — | — |
| Shares Outstanding | — | $59M | $58M | $58M | $57M | $57M | $57M | $57M |
Negative equity and leverage
According to current market data, Embecta trades at a P/E of 2.15 and an EV/EBITDA of 3.71, which, as reported in financial statements, suggests that investors are pricing the company as a terminal-value asset rather than a growth-oriented medical technology firm with future innovation potential.
These depressed multiples appear to reflect deep market skepticism regarding the company's ability to successfully pivot from legacy consumables to proprietary patch pump technology. Investors should monitor whether these valuations represent a deep-value opportunity or a rational adjustment to the risks of revenue erosion and high debt service requirements.
Based on Embecta's reported figures, ROIC has trended downward from 13.2% in 2025Q3 to a mere 2.8% in 2026Q2, indicating that the company is struggling to generate adequate returns on its invested capital as it navigates the transition to an independent operating structure.
The sharp decline in ROIC suggests that the firm's manufacturing scale advantage is being offset by rising operational costs and the burden of its debt-heavy capital structure. This trend warrants further investigation into whether the company can stabilize its return profile as it moves past the initial spin-off dis-synergies.
As reported in recent financial statements, Embecta's cash conversion cycle has fluctuated significantly, reaching 155 days in 2026Q2, which suggests that the company faces ongoing challenges in managing its inventory and distributor payment terms compared to its historical performance and industry peers.
The elevated days inventory outstanding, which hit 156 days in 2026Q2, indicates potential inefficiencies in managing high-volume manufacturing output against variable demand. This lack of working capital discipline appears to be a primary driver of the company's inconsistent cash flow generation and liquidity strain.
Based on the company's quarterly filings, the current ratio has remained relatively stable at 2.46 in 2026Q2, yet the underlying cash position is being pressured by debt service obligations and the need to fund R&D for the company's new insulin patch pump technology.
While the current ratio appears adequate on the surface, the company's reliance on debt financing and negative equity position suggests that its liquidity profile is more vulnerable than the headline numbers imply. Investors should monitor the company's ability to maintain these ratios without further eroding its cash reserves.
As evidenced by the company's negative equity and volatile earnings, the P/E ratio is a fundamentally flawed metric for Embecta, as it obscures the impact of high interest expenses and non-recurring spin-off costs that distort the true underlying earning power of the business.
Analysts should instead focus on EV/EBITDA or free cash flow yield to better understand the company's operational performance, as these metrics are less sensitive to the capital structure distortions inherent in a post-spin entity. Relying on P/E in this context may lead to an inaccurate assessment of the company's valuation relative to its peers.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EMBC stock.
Embecta Corp.'s current P/E ratio is 2.0x. The historical average is 9.7x.
Embecta Corp.'s current EV/EBITDA is 3.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.7x.
Based on historical data, Embecta Corp. is trading at a P/E of 2.0x. Compare with industry peers and growth rates for a complete picture.
Embecta Corp.'s current dividend yield is 17.95% with a payout ratio of 36.7%.
Embecta Corp. has 62.9% gross margin and 30.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Embecta Corp.'s Debt/EBITDA ratio is 3.8x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.